RARE Stock UPDATES Ultragenyx Pharmaceutical Inc. (RARE) 55.69

New Post Public Reply Private Reply Replies (0) Message Board

Sep 18, 2014 at 8:07 PM

Ultragenyx Pharmaceutical Inc. (RARE) 55.69 $RARE

IPO Stock Watch: ReWalk Joins An Exclusive IPO Club
at Investor's Business Daily - Mon Sep 15, 5:56PM CDT
ReWalk Robotics (RWLK) stock rose 45% Monday on the heels of its eye-popping IPO Friday that joined an exclusive group. ReWalk was the fifth initial public offering this year to fly 100% or more on its first day of trading and the only IPO since 2000...

Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia
GlobeNewswire - Mon Sep 15, 9:04AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of the investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). The cumulative 16-month data, combining the four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.

Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 04, 9:34AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 12:55pm ET at the Grand Hyatt in New York.

Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 7
GlobeNewswire - Wed Sep 03, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of positive interim data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome). The data are being presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Innsbruck, Austria.

Ultragenyx to Present at the Baird Health Care Conference
GlobeNewswire - Wed Aug 27, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Tom Kassberg, the company's Chief Business Officer, will be presenting at the Robert W. Baird & Co. 2014 Health Care Conference on September 3, 2014 at 1:45pm ET in New York.

3 Big-Volume Biotech Stocks to Trade for Breakouts
at The Street - Tue Aug 26, 6:00AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Ultragenyx (RARE) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:41AM CDT
Ultragenyx (RARE) Shares March Higher, Can It Continue?

Company News for August 12, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:10AM CDT
Companies in the News are: DF,SYY,VHI,RARE

Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 11, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the second quarter ended June 30, 2014.

3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.

Why Ultragenyx Pharmaceutical (RARE) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 7:30AM CDT
Ultragenyx Pharmaceutical (RARE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.

Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Aug 06, 8:04AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Wedbush PacGrow Life Sciences Management Access Conference on August 13, 2014 at 3:40pm ET in New York and at the Canaccord Genuity Growth Conference on August 14, 2014 at 10:30am ET in Boston.

Ultragenyx Announces License of Intellectual Property for the Treatment of Epilepsy and Other Seizure-Related Disorders With Triheptanoin
GlobeNewswire - Tue Aug 05, 8:01AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced a license agreement with UniQuest Pty Limited for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin (UX007). The intellectual property originated from research on epilepsy and other neurologic models conducted at The University of Queensland.

Ultragenyx Pharmaceutical (RARE) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 8:39AM CDT
Ultragenyx Pharmaceutical (RARE) was a big mover last session, as its shares rose over 5% on the day.

3 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 31, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President
GlobeNewswire - Wed Jul 23, 8:00AM CDT
Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, effective August 25, 2014. In this role, Dr. Agarwal will provide strategic leadership and direction to Clinical Operations, Clinical Development, Regulatory Affairs, Biometrics, Pharmacovigilance, and Non-Clinical Research. He will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's CEO, and will serve on the Senior Management Team.

Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.

Ultragenyx concludes public offering of 2.32m common shares, including exercise of underwriters' option
M2 - Tue Jul 15, 8:19AM CDT
Biopharmaceutical company Ultragenyx Pharmaceutical (NasdaqGS:RARE) revealed on Monday the completion of its public offering of 2,319,951 shares of common stock.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WAX Collect Unveils Modular Flex Insurance for Watches

WAX Collect Pioneers Customized Insurance with WAX Flex™ In a world where even a simple escapement can change the watch industry, WAX Collect is shaking things up with its WAX Flex™, rolling out a tailor-made insurance product specifically for watch collectors who refuse to settle for one-size-fits-all coverage. It's the first of its kind in modular approaches,...

Immunic, Inc. Steams Ahead: Phase 3 Trials Hinge on MS Data

A Pivotal Moment for Immunic We’re staring down a critical December for Immunic, Inc. as they trot out top-line data for their Phase 3 ENSURE trials aimed at relapsing multiple sclerosis (MS). Now, I’m all ears wondering if those trials can hold water — success could morph them from a tinkering biotech into a commercial giant. For market vultures like us,...

Toronto's Distillery Winter Village Kicks Off 2026

Toronto's Holiday Spirit Ignites Toronto just cranked up the holiday spirit with the lighting of a 55-foot Christmas tree at The Distillery Winter Village. Let me tell you, it's a sight that could warm your innards on the coldest winter night. Presented by Quince, this winter wonderland opened its doors for 2026—and it's looking like they're pulling out all the stops...

Shorr Packaging's Sustainable Edge: EcoVadis Silver Triumph

EcoVadis Silver Badge: Shorr's Green Path Imagine this: Shorr Packaging strutting around with an EcoVadis Silver Badge pinned to its chest for not one, not two, but three years now. That's right, Shorr Packaging's been elbowing its way to the top tier with their sustainability drive, ranked in the 93rd percentile. For those not keeping score, that's top-notch, considering...

Coastal Financial Faces $470M Wipeout: Investor Alert

Revelations Hit Coastal Financial Hard Alright, pull up a chair and let’s chew over what just happened with Coastal Financial Corporation (NASDAQ: CCB). This is the sort of deal that makes seasoned investors shake their heads in disbelief. Between October 28, 2024, and July 29, 2026, anyone buying into Coastal was buying into a mess they didn’t sign up for. We're...

Robbins LLP Calls Everest Investors for Class Action

Everest Group's Legal Storm: A Call to Action Jumping straight into the proverbial storm, Everest Group, Ltd. (NYSE:EG) is snagged in a mess of their own creation, leaving investors holding the short end of the stick. This class action suits up post-haste, citing a cocktail of mismanagement and downright dodgy disclosures regarding their U.S. casualty insurance gambit....

City National Bank Names New VP for Real Estate

Banking on Growth with Jeffrey LaBauve Jeffery LaBauve struts into the picture, ready to take the helm as City National Bank's new head of Commercial Real Estate Banking. And let me tell ya, the word on the street is he's raring to ramp things up. After almost two decades at Comerica Bank, this guy’s not here for a measly lap around the track—he's got plans to double...

Porter Capital Expands Finance Solutions for Growth

Expanding Financial Horizons with Term Loans Rolling into Birmingham's Porter Capital story today, there's a new chapter penned with term loans and lines of credit – it’s not just for the businesses strapped for cash but those eyeing growth without the chains of rigid bank criteria. For over 35 years, these folks have been the grease in the economy's wheels, slinging...

Purdue's xGTT: Pioneering a New Trust Standard in Tech

A Bold New Benchmark in Tech Trust You've got to hand it to the folks at Purdue's Krach Institute—they're not dancing around the fringes but diving straight into the thick of it with their Global Trusted Tech Standard, or xGTT. This isn't just another checkbox for compliance nerds. The xGTT is all about building trust in technology that's woven with democratic values...

Data Center Transformers on the Brink of a Boom

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...